首页> 外文期刊>Case Reports in Nephrology >A Case of Systemic Lupus Erythematosus/Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome with Dissociated Pathological and Immunological Findings
【24h】

A Case of Systemic Lupus Erythematosus/Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome with Dissociated Pathological and Immunological Findings

机译:Systemic Lupus红斑狼疮/抗癫痫细胞质细胞质抗体相关的血管炎与解离病理和免疫发现重叠综合症

获取原文
           

摘要

Systemic lupus erythematosus/antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome (SLE/AAV OS) describes a pathological condition that presents with overlapping features of two diseases. There have been few reports of SLE/AAV OS and none from Japan. We present the case of a 59-year-old woman admitted with chief complaints of fever and decreased renal function. SLE was suspected due to the identification of four items from the diagnostic criteria of the American College of Rheumatology, including positivity for anti-ds-DNA and antinuclear antibodies. However, pathological findings from the kidney biopsy suggested pauci-immune crescentic glomerulonephritis. She was also diagnosed with AAV according to the Chapel Hill Consensus Conference (CHCC) 2012 definitions and the classification algorithm of AAV. SLE/AAV OS was suspected, we started immunosuppressant therapy, and subsequently her renal function improved. In previous reports, initial immunological and pathological findings generally concur. In cases where clinical and pathological features appear to conflict, as in the present case, a treatment strategy decision should be based on pathological and immunological findings to improve the prognosis of OS.
机译:系统性红斑狼疮/抗癫痫术细胞质抗体相关的血管炎重叠综合征(SLE / AAV OS)描述了具有两种疾病的重叠特征的病理条件。关于SLE / AAV OS的报道很少,没有来自日本。我们提出了一个59岁女性的案例,承认发烧的主要投诉和肾功能下降。由于鉴定了来自美国风湿病学诊断标准的四个项目,因此怀疑SLE,包括抗DS-DNA和抗核抗体的阳性。然而,来自肾脏活检的病理发现表明假冒新月形肾小球肾炎。根据Chapel Hill共识(CHCC)2012的定义和AAV分类算法,她还被诊断出患有AAV。 SLE / AAV OS怀疑,我们开始免疫抑制治疗,随后她的肾功能改善了。在以前的报告中,初始免疫学和病理发现通常会同意。在临床和病理特征似乎发生冲突的情况下,如在本案中,治疗战略决定应基于病理和免疫发现来改善OS的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号